$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000114420414028740 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$8.259M	$7.462M	$3.833M
YoY Change	133.9%	94.68%	-17.43%
Cost Of Revenue	$5.102M	$3.021M	$1.712M
YoY Change	212.62%	76.46%	-54.78%
Gross Profit	$3.157M	$4.441M	$2.121M
YoY Change	66.25%	109.38%	147.78%
Gross Profit Margin	38.22%	59.51%	55.34%
Selling, General & Admin	$5.800M	$4.300M	$2.900M
YoY Change	45.0%	48.28%	-6.45%
% of Gross Profit	183.72%	96.83%	136.73%
Research & Development	$15.20M	$14.52M	$9.256M
YoY Change	40.96%	56.85%	73.4%
% of Gross Profit	481.53%	326.91%	436.4%
Depreciation & Amortization	$1.000M	$1.000M	$400.0K
YoY Change	66.67%	150.0%	0.0%
% of Gross Profit	31.68%	22.52%	18.86%
Operating Expenses	$15.20M	$14.52M	$9.256M
YoY Change	40.96%	56.85%	73.4%
Operating Profit	-$17.85M	-$14.39M	-$10.01M
YoY Change	38.4%	43.78%	33.99%
Interest Expense	$51.00K	$52.00K	$22.00K
YoY Change	13.33%	136.36%	633.33%
% of Operating Profit
Other Income/Expense, Net	$18.00K	$0.00
YoY Change
Pretax Income	-$17.86M	-$13.81M	-$9.979M
YoY Change	41.46%	38.39%	36.03%
Income Tax	$0.00		$17.00K
% Of Pretax Income
Net Earnings	-$17.86M	-$13.81M	-$9.996M
YoY Change	41.41%	38.16%	36.26%
Net Earnings / Revenue	-216.3%	-185.07%	-260.79%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.642M	-$1.327M	-$1.351M
COMMON SHARES
Basic Shares Outstanding	209.3M shares	209.1M shares	147.9M
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$152.5M	$112.8M	$44.30M
YoY Change	275.62%	154.63%	114.01%
Cash & Equivalents	$103.9M	$109.9M	$9.023M
Short-Term Investments	$149.7M	$2.900M	$35.30M
Other Short-Term Assets	$269.0K	$504.0K	$886.0K
YoY Change	1245.0%	-43.12%	400.56%
Inventory
Prepaid Expenses	$5.116M	$4.626M	$2.167M
Receivables	$3.719M	$4.466M	$2.602M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$166.6M	$128.9M	$51.72M
YoY Change	267.25%	149.16%	95.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.12M	$14.27M	$11.62M
YoY Change	13.54%	22.84%	46.14%
Goodwill	$57.91M	$58.62M	$33.14M
YoY Change	74.73%	76.88%	0.0%
Intangibles	$15.09M	$15.92M
YoY Change
Long-Term Investments	$56.40M		$1.100M
YoY Change
Other Assets	$159.0K	$159.0K	$350.0K
YoY Change	-52.54%	-54.57%	0.0%
Total Long-Term Assets	$145.4M	$89.73M	$46.98M
YoY Change	205.74%	90.98%	11.34%
TOTAL ASSETS
Total Short-Term Assets	$166.6M	$128.9M	$51.72M
Total Long-Term Assets	$145.4M	$89.73M	$46.98M
Total Assets	$312.0M	$218.6M	$98.70M
YoY Change	235.77%	121.47%	43.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.495M	$4.018M	$2.173M
YoY Change	52.58%	84.91%	-26.56%
Accrued Expenses	$11.00M	$8.208M	$5.842M
YoY Change	52.26%	40.5%	30.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$900.0K	$1.000M	$400.0K
YoY Change	50.0%	150.0%
Total Short-Term Liabilities	$17.48M	$13.72M	$9.253M
YoY Change	55.29%	48.22%	18.01%
LONG-TERM LIABILITIES
Long-Term Debt	$900.0K	$1.100M	$1.500M
YoY Change	-52.63%	-26.67%	275.0%
Other Long-Term Liabilities	$1.507M	$1.562M	$10.40M
YoY Change	-85.78%	-84.98%	70.49%
Total Long-Term Liabilities	$1.507M	$1.562M	$11.90M
YoY Change	-87.94%	-86.87%	83.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.48M	$13.72M	$9.253M
Total Long-Term Liabilities	$1.507M	$1.562M	$11.90M
Total Liabilities	$30.26M	$27.54M	$21.14M
YoY Change	27.72%	30.29%	47.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$441.8M	-$424.0M	-$368.2M
YoY Change	16.03%	15.16%	9.25%
Common Stock	$2.386M	$2.097M	$1.517M
YoY Change	55.74%	38.23%	23.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M	$2.450M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	455.4K shares	455.4K shares	455.4K shares
Shareholders Equity	$281.7M	$191.1M	$77.57M
YoY Change
Total Liabilities & Shareholders Equity	$312.0M	$218.6M	$98.70M
YoY Change	235.77%	121.47%	43.81%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$17.86M	-$13.81M	-$9.996M
YoY Change	41.41%	38.16%	36.26%
Depreciation, Depletion And Amortization	$1.000M	$1.000M	$400.0K
YoY Change	66.67%	150.0%	0.0%
Cash From Operating Activities	-$11.00M	-$20.43M	-$10.58M
YoY Change	44.74%	93.05%	150.78%
INVESTING ACTIVITIES
Capital Expenditures	-$900.0K	-$900.0K	-$1.500M
YoY Change	-47.06%	-40.0%	87.5%
Acquisitions
YoY Change
Other Investing Activities	-$101.8M	$10.60M	-$3.400M
YoY Change	6262.5%	-411.76%	36.0%
Cash From Investing Activities	-$102.8M	$9.701M	-$4.974M
YoY Change	3112.5%	-295.03%	52.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$6.425M
YoY Change		-100.0%	-18.91%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	107.7M	$1.170M	$7.181M
YoY Change	2347.73%	-83.71%	-1.07%
NET CHANGE
Cash From Operating Activities	-11.00M	-$20.43M	-$10.58M
Cash From Investing Activities	-102.8M	$9.701M	-$4.974M
Cash From Financing Activities	107.7M	$1.170M	$7.181M
Net Change In Cash	-6.100M	-$9.560M	-$8.376M
YoY Change	-4.69%	14.14%	3525.97%
FREE CASH FLOW
Cash From Operating Activities	-$11.00M	-$20.43M	-$10.58M
Capital Expenditures	-$900.0K	-$900.0K	-$1.500M
Free Cash Flow	-$10.10M	-$19.53M	-$9.083M
YoY Change	71.19%	115.03%	165.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15000000	USD
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	209275650	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
CY2014Q1	dei	Trading Symbol TradingSymbol	NVAX
CY2014Q1	nvax	Cash Held In Foreign Banks CashHeldInForeignBanks	300000	USD
CY2013Q3	nvax	Novavax Shares Issued NovavaxSharesIssued	15600000	shares
CY2014Q1	nvax	Reclassification From General Administrative Expenses To Research Development Expenses ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses	200000	USD
CY2014Q1	nvax	Remaining Gross Proceeds Sale Of Stock RemainingGrossProceedsSaleOfStock	15000000	USD
CY2014Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	1990000	USD
CY2013Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	392000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4018000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5985000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4466000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1911000	USD
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-99000	USD
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-94000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8208000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10411000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	90000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	839000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	615279000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	612900000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1040000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	483000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15359430	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15722925	shares
CY2014Q1	us-gaap	Assets Assets	218599000	USD
CY2013Q4	us-gaap	Assets Assets	235125000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	128873000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	145001000	USD
CY2014Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2907000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	13597000	USD
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2907000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	12981000	USD
CY2014Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	2907000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	13597000	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains		USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	616000	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss		USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss		USD
CY2013Q3	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	41900000	USD
CY2014Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	214000	USD
CY2013Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	422000	USD
CY2014Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	105000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	108000	USD
CY2014Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	191000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	195000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119471000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9023000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17399000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109921000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9550000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8376000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	209711305	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	209110744	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	209255875	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	208655314	shares
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	2097000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	2091000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14559000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9957000	USD
CY2014Q1	us-gaap	Contract Revenue Cost ContractRevenueCost	3021000	USD
CY2013Q1	us-gaap	Contract Revenue Cost ContractRevenueCost	1712000	USD
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	5472000	USD
CY2013Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	376000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	21847000	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	3441000	USD
CY2014Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	13838000	USD
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	475000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	470000	USD
CY2014Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8710000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8502000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	57000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	271000	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	980000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	449000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	10000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents		USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11600000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
CY2014Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.2	pure
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	738000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1107000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	830000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1107000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1107000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1107000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1107000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	17000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4308000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2870000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	58621000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	58707000	USD
CY2013Q1	us-gaap	Goodwill Goodwill	33141000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-180000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16656000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15918000	USD
CY2014Q1	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-86000	USD
CY2013Q1	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments		USD
CY2014Q1	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	6113000	USD
CY2013Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	4988000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13810000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9979000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4007000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1590000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2559000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1591000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-215000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	703000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1516000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-54000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1081000	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-769000	USD
CY2014Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1125000	USD
CY2013Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15918000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16250000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	52000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	22000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	52000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	20000	USD
CY2014Q1	us-gaap	Investment Income Net InvestmentIncomeNet	12000	USD
CY2013Q1	us-gaap	Investment Income Net InvestmentIncomeNet	48000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20431000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10583000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	27539000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	31891000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	218599000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	235125000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13715000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18122000	USD
CY2014Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	861000	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1004000	USD
CY2014Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	615000	USD
CY2013Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal"> Note 1 - Organization</p> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in; font-size-adjust: none; font-stretch: normal"> Novavax, Inc. ("Novavax," and together with its subsidiary, "Novavax AB," the "Company") is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company's product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for seasonal influenza, pandemic influenza and respiratory syncytial virus ("RSV").</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in; font-size-adjust: none; font-stretch: normal">  </p> <!--EndFragment--></div> </div>
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1170000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7181000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9701000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4974000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-13810000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-9996000	USD
CY2014Q1	us-gaap	Notes Payable Current NotesPayableCurrent	852000	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	877000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	573000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	159000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	159000	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14385000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10005000	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	504000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-133000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-749000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	39000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	615000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax		USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1562000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1568000	USD
CY2014Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-213000	USD
CY2013Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-240000	USD
CY2013Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	200000	USD
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities		USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8718000	USD
CY2013Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	22000000	USD
CY2014Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	889000	USD
CY2013Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1542000	USD
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4626000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3044000	USD
CY2014Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; font-size-adjust: none; font-stretch: normal"> <strong><em>Reclassification</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0.25in; font-size-adjust: none; font-stretch: normal"> <strong> </strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in; font-size-adjust: none; font-stretch: normal"> In its Quarterly Report on Form 10-Q for the period ended March 31, 2013, the Company had recorded $0.2 million of patent costs within research and development expenses for the three months ended March 31, 2013. The Company subsequently determined that patent costs should be a general and administrative expense and these costs have been shown as a general and administrative expense for the period.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in; font-size-adjust: none; font-stretch: normal">  </p> <!--EndFragment--></div> </div>
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6425000	USD
CY2014Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
CY2013Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	809000	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-168000	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-39000	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	10590000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5235000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	51000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1345000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14270000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14251000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	6000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	14000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14518000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9256000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	336000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1417000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	758000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	757000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-423956000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410146000	USD
CY2014Q1	us-gaap	Revenues Revenues	7462000	USD
CY2013Q1	us-gaap	Revenues Revenues	3833000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	16667	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6923	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0222	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0134	pure
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1040000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	483000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	16667	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6793	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7372	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5247	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0062	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.63
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.00
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	208927	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	148448	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1400000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30300000	USD
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	191060000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	203234000	USD
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; font-size-adjust: none; font-stretch: normal"> <strong><em>Use of Estimates</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; font-size-adjust: none; font-stretch: normal">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in; font-size-adjust: none; font-stretch: normal"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> <!--EndFragment--></div> </div>

Files In Submission

Name	View Source	Status
0001144204-14-028740-index-headers.html	Edgar Link	pending
0001144204-14-028740-index.html	Edgar Link	pending
0001144204-14-028740.txt	Edgar Link	pending
0001144204-14-028740-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nvax-20140331.xml	Edgar Link	completed
nvax-20140331.xsd	Edgar Link	pending
nvax-20140331_cal.xml	Edgar Link	unprocessable
nvax-20140331_def.xml	Edgar Link	unprocessable
nvax-20140331_lab.xml	Edgar Link	unprocessable
nvax-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v376157_10q.htm	Edgar Link	pending
v376157_ex31-1.htm	Edgar Link	pending
v376157_ex31-2.htm	Edgar Link	pending
v376157_ex32-1.htm	Edgar Link	pending
v376157_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2014 Q2 Form 10-Q Financial Statement

#000114420414028740 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2014 Q2 Form 10-Q Financial Statement

#000114420414028740 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax